Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KHK6640 Phase 1 SAD in Japanese AD Patients
NCT02377713Phase 1Completed
- Sponsor
- Kyowa Kirin
- Start
- Mar 2015
- Primary completion
- Sep 2016
- Modality
- Peptides, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing KHK6640 with Placebo (2 arms). Primary endpoint: Number of Participants with Adverse Events as a Measure of Safety and Tolerability up to 90 days. Started Mar 2015; status: completed.
02
Drugs
KHK6640
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02377713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02377713.